Reveromycin A inhibits antigen receptor-mediated antigen presentation by B lymphoma cells via its effect on intracellular trafficking of the antigen.
Reveromycin A (Rev.A) is an inhibitor of epidermal growth factor-dependent cell growth that is produced from the culture broth of an actinomycete strain. Rev.A was assessed for its ability to regulate antigen (Ag) presentation by A20-HL B lymphoma cells bearing trinitrophenyl (TNP)-specific surface IgM (sIgM) to cloned T cells specific for OVA(323-339)/I-Ad. Rev.A-treatment inhibited the presentation of Ag internalized via sIgM, but not of Ag via fluid-phase pinocytosis. Rev.A-treatment decreased protein synthesis, but a similar decrease in protein synthesis by cycloheximide induced much less inhibition of sIgM-mediated Ag presentation. Rev.A-treatment decreased the rate of re-expression of sIgM in A20-HL cells, the amount of Ag internalized via sIgM during 3 hours of incubation, and the generation of antigenic peptides from TNP-OVA internalized via sIgM. Rev.A-treatment was suggested to affect intracellular trafficking from early endosomes into late endocytic compartments of Ag internalized via sIgM. Rev.A might provide a useful tool for studying intracellular transport of Ag, especially Ag internalized via sIgM.
Tanaka
Yuriko
Y
Department of Immunology, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan.
Ishikawa
Fumio
F
Osada
Hiroyuki
H
Imajoh-Ohmi
Shinobu
S
Uchida
Tetsuya
T
Kakiuchi
Terutaka
T
D005434:Flow Cytometry; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology; D011714:Pyrans / Q000627:therapeutic use*; D011947:Receptors, Antigen, B-Cell / Q000187:drug effects* / Q000276:immunology; D013141:Spiro Compounds / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
D011714:Pyrans; D011947:Receptors, Antigen, B-Cell; D013141:Spiro Compounds; C068098:reveromycin A